SYDNEY TANG: Open Payments
NPI 1508592759 · GLENDALE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,564 in 151 payments from 16 companies in 2025. Trend: 2023 $835 · 2024 $2,067 · 2025 $3,564
Food & beverage: $3,488Education: $76
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 18 | $537 |
| Janssen Biotech, Inc. | 29 | $521 |
| Incyte Corporation | 21 | $438 |
| Galderma Laboratories, L.P. | 13 | $326 |
| ABBVIE INC. | 16 | $306 |
| Organon LLC | 6 | $302 |
| Regeneron Healthcare Solutions, Inc. | 8 | $244 |
| Arcutis Biotherapeutics, Inc. | 10 | $234 |
| Amgen Inc. | 13 | $226 |
| Novartis Pharmaceuticals Corporation | 5 | $166 |
Products named: DUPIXENT, TREMFYA, OPZELURA, NEMLUVIO, VTAMA, SKYRIZI, Zoryve, Otezla.
Industry payments across CA — which companies pay providers there.
